高密度脂蛋白输液疗法:一篇综述
H Bryan Brewer1, Ernst J Schaefer2, Borek Foldyna3
1HDL Therapeutics, Vero Beach, FL, USA (Dr Brewer).
Journal of clinical lipidology
|May 23, 2024
概括
高密度脂蛋白 (HDL) 输液显示出动脉样硬化回归的潜力,但结果各不相同. 高密度胆固醇制剂,患者群体和评估方法的差异可能解释临床试验中不一致的结果.
科学领域:
- 心血管医学 心血管医学
- 生物化学 生物化学
- 医疗成像医学成像
背景情况:
- 增加的富含胆固醇,非化的动脉动脉瘤比传统标志物更好地预测心肌梗塞.
- 低高密度脂蛋白 (HDL) 胆固醇是冠状动脉疾病 (CAD) 的独立危险因素.
- 小的,缺乏脂质的preβ-1 HDL颗粒对细胞胆固醇排放有有效作用.
研究的目的:
- 审查对动脉样硬化回归的HDL输液治疗的动物和人类研究.
- 探索在HDL输液研究中可变结果的原因.
主要方法:
- 对动物研究的审查,证明HDL对大动脉动脉样硬化的影响.
- 使用HDL模仿剂和本地HDL输液的人类临床试验的分析.
- 检查使用血管内超声波和计算冠状动脉血管学进行动脉样硬化评估的研究.
主要成果:
- 在动物模型中,HDL输液减少了大动脉动脉样硬化.
- 一些使用HDL模仿剂或复合物的人类研究给出了冠状动脉样硬化进展的负面结果.
- 一项使用自身脱脂HDL输液的研究显示,家族高胆固醇患者冠状动脉动脉瘤的显著回归.
结论:
- 高密度胆固醇 (HDL) 输液治疗对动脉样硬化回归有希望,特别是在自身脱脂的高密度胆固醇 (HDL) 中.
- 结果的变化可能源于HDL制剂,患者选择和成像评估技术的差异.
- 需要进一步的研究,以优化基于HDL的治疗心血管疾病.
更多相关视频
11:13Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
Published on: May 9, 2019
8.8K
03:42Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.5K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:28IV Infusion to Oral Dosing: Conversion Methods
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...